Close Menu

NEW YORK – Medicare Administrative Contractor CGS Administrators has aligned its coverage for melanoma risk stratification tests in patients with cutaneous melanoma, including Castle Biosciences' DecisionDx-Melanoma test.

The revised local coverage determination goes into effect Dec. 21 and aligns coverage for molecular diagnostic tests used to aid in risk stratification of melanoma patients with Palmetto GBA's previously announced expanded LCD.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.